Thomas, welcome.
Just give me an overview, if you would, of the current state of
health care in Europe.
It's a global market, so, by definition, European health care
companies compete on the same standards that everyone else does.
There are a few specificities
that I think are interesting.
First, health care companies in Europe tend to be a bit less
exposed to the patent cliff that is on the mind
of so many health leaders.
And so, for instance . . . I mean, we do have countries in
Europe that are revising their GDP productions upwards because
of the dynamics of the GPL-1--companies like Novo
Nordisk that have been very much growing through those products.
And then there's always with Europe, some regulations news --
some of those that will help innovation.
I think the EU Commission actually introduced something
for joint clinical assessments and joint medical devices review
that will kick in this year.
And so definitely that should help innovation, as well as a
potentially an AI regulation act that will come later this year.
I mean, you spoke about regulation there, innovation.
What are the sort of key trends do you think will be shaping
health care this year?
I mean, definitely innovation and AI--that's definitely top of mind.
It's also an area where Europe is very, very active.
And I think we definitely just barely scratch the surface on
how much AI can reshape the health care industry And what's
And what’s top of mind for industry leaders?
What are they telling you?
What are you speaking to them about?
I think at the end of it is very much getting back to the basics.
It's a market where fundamentals are still very much strong.
It's still about innovation.
There's question on where do you get that innovation from?
Do you want to do it internally?
Do you want to get it externally?
Do you want to retain a traditional R&D model, or do
you want to reshape that
with AI? Do you want to get it in the US or in Europe, or do
you want to tap into China?
So I think the questions are more
how do we get that innovation?
But fundamentally, it's still very much getting back to the
basics of that market.
Thomas, thank you so much for your time.
Thank you very much.